New at #ESMO26: @mvnegrao @UTMDAnderson discusses the hepatic safety of first-line olomorasib plus pembrolizumab and chemo in KRAS G12C-mutant non–small cell lung cancer.

Targeted Oncology· @TargetedOnc · X·2026-10-26 20:34· 2 天前评分45

正文 · 原文

Watch: https://www.targetedonc.com/view/olomorasib-combination-manageable-liver-toxicity-kras-g12c-mutant-nsclc

69 浏览 · 0 赞 · 0 转发 · 0 回复

会议摘要

2683P按 NSCLC, metastatic 对上

First-line (1L) olomorasib + pembrolizumab in KRAS G12C-mutant NSCLC: Updated results from LOXO-RAS-20001 and SUNRAY-01

https://esmocongress.esmo.org

来源：Targeted Oncology · x.com